Guest guest Posted March 14, 2004 Report Share Posted March 14, 2004 Becky, CTLA4-Ig gets its ugly name from the fact that it is a cytotoxic T lymphocyte-associated antigen 4 fused to the heavy chain constant region of human IgG1 (a soluble fusion protein). It's the first agent in a new class of biologics called costimulation blockers. CTLA4-Ig inhibits T-cell activation. NEJM November 13, 2003 " Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4Ig " : http://content.nejm.org/cgi/content/short/349/20/1907 I'll tell you where to go! Mayo Clinic in Rochester http://www.mayoclinic.org/rochester s Hopkins Medicine http://www.hopkinsmedicine.org Re: [ ] Hi all. > > > Welcome to the group! I don't know of anyone here in a trial for that > agent (BMS188667 = CTLA4-Ig), but not everyone here posts. I see in the > business news that Repligen and BMS are fighting over the patents, so > there must be something good going on there, LOL. > > > Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.